These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

159 related articles for article (PubMed ID: 32302330)

  • 1. Serum levels of bone sialoprotein correlate with portal pressure in patients with liver cirrhosis.
    Benz F; Bogen A; Praktiknjo M; Jansen C; Meyer C; Wree A; Demir M; Loosen S; Vucur M; Schierwagen R; Tacke F; Trebicka J; Roderburg C
    PLoS One; 2020; 15(4):e0231701. PubMed ID: 32302330
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Circulating Elastin Fragments Are Not Affected by Hepatic, Renal and Hemodynamic Changes, But Reflect Survival in Cirrhosis with TIPS.
    Nielsen MJ; Lehmann J; Leeming DJ; Schierwagen R; Klein S; Jansen C; Strassburg CP; Bendtsen F; Møller S; Sauerbruch T; Karsdal MA; Krag A; Trebicka J
    Dig Dis Sci; 2015 Nov; 60(11):3456-64. PubMed ID: 26138655
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Osteopontin: A non-invasive parameter of portal hypertension and prognostic marker of cirrhosis.
    Bruha R; Jachymova M; Petrtyl J; Dvorak K; Lenicek M; Urbanek P; Svestka T; Vitek L
    World J Gastroenterol; 2016 Mar; 22(12):3441-50. PubMed ID: 27022226
    [TBL] [Abstract][Full Text] [Related]  

  • 4. CXCL9 is a prognostic marker in patients with liver cirrhosis receiving transjugular intrahepatic portosystemic shunt.
    Berres ML; Asmacher S; Lehmann J; Jansen C; Görtzen J; Klein S; Meyer C; Strunk HM; Fimmers R; Tacke F; Strassburg CP; Trautwein C; Sauerbruch T; Wasmuth HE; Trebicka J
    J Hepatol; 2015 Feb; 62(2):332-9. PubMed ID: 25457205
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Chemokine (C-X-C motif) ligand 11 levels predict survival in cirrhotic patients with transjugular intrahepatic portosystemic shunt.
    Berres ML; Lehmann J; Jansen C; Görtzen J; Meyer C; Thomas D; Zimmermann HW; Kroy D; Schumacher F; Strassburg CP; Sauerbruch T; Trautwein C; Wasmuth HE; Trebicka J
    Liver Int; 2016 Mar; 36(3):386-94. PubMed ID: 26212075
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Kupffer cells are activated in cirrhotic portal hypertension and not normalised by TIPS.
    Holland-Fischer P; Grønbæk H; Sandahl TD; Moestrup SK; Riggio O; Ridola L; Aagaard NK; Møller HJ; Vilstrup H
    Gut; 2011 Oct; 60(10):1389-93. PubMed ID: 21572121
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Non-invasive aspartate aminotransferase to platelet ratio index correlates well with invasive hepatic venous pressure gradient in cirrhosis.
    Kirnake V; Arora A; Sharma P; Goyal M; Chawlani R; Toshniwal J; Kumar A
    Indian J Gastroenterol; 2018 Jul; 37(4):335-341. PubMed ID: 30178093
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Prospective evaluation of anticoagulation and transjugular intrahepatic portosystemic shunt for the management of portal vein thrombosis in cirrhosis.
    Senzolo M; M Sartori T; Rossetto V; Burra P; Cillo U; Boccagni P; Gasparini D; Miotto D; Simioni P; Tsochatzis E; A Burroughs K
    Liver Int; 2012 Jul; 32(6):919-27. PubMed ID: 22435854
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Soluble TNF-alpha-receptors I are prognostic markers in TIPS-treated patients with cirrhosis and portal hypertension.
    Trebicka J; Krag A; Gansweid S; Schiedermaier P; Strunk HM; Fimmers R; Strassburg CP; Bendtsen F; Møller S; Sauerbruch T; Spengler U
    PLoS One; 2013; 8(12):e83341. PubMed ID: 24386183
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Portal pressure gradient and serum albumin: A simple combined parameter associated with the appearance of ascites in decompensated cirrhosis treated with transjugular intrahepatic portosystemic shunt.
    Zhao D; Zhang G; Wang M; Zhang C; Li J
    Clin Mol Hepatol; 2019 Jun; 25(2):210-217. PubMed ID: 30897897
    [TBL] [Abstract][Full Text] [Related]  

  • 11. APTR is a prognostic marker in cirrhotic patients with portal hypertension during TIPS procedure.
    Yu S; Qi Y; Jiang J; Wang H; Zhou Q
    Gene; 2018 Mar; 645():30-33. PubMed ID: 29274906
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pathophysiological role of prostanoids in coagulation of the portal venous system in liver cirrhosis.
    Queck A; Thomas D; Jansen C; Schreiber Y; Rüschenbaum S; Praktiknjo M; Schwarzkopf KM; Mücke MM; Schierwagen R; Uschner FE; Meyer C; Clària J; Zeuzem S; Geisslinger G; Trebicka J; Lange CM
    PLoS One; 2019; 14(10):e0222840. PubMed ID: 31644538
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Changes in portal hemodynamics after TIPS in liver cirrhosis and portal hypertension.
    Palikhe M; Xue H; Jha RK; Li YC; Yuan J; Wang J; Zhang M
    Scand J Gastroenterol; 2013 May; 48(5):570-6. PubMed ID: 23452021
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Rapid change of liver stiffness after variceal ligation and TIPS implantation.
    Piecha F; Paech D; Sollors J; Seitz HK; Rössle M; Rausch V; Mueller S
    Am J Physiol Gastrointest Liver Physiol; 2018 Feb; 314(2):G179-G187. PubMed ID: 29051188
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Enhanced processing of von Willebrand factor reflects disease severity and discriminates severe portal hypertension in cirrhosis.
    Langholm LL; Manon-Jensen T; Karsdal MA; Bendtsen F; Leeming DJ; Møller S
    Eur J Gastroenterol Hepatol; 2019 Aug; 31(8):1040-1048. PubMed ID: 30768435
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Transjugular intrahepatic portosystemic shunt: impact on systemic hemodynamics and renal and cardiac function in patients with cirrhosis.
    Busk TM; Bendtsen F; Poulsen JH; Clemmesen JO; Larsen FS; Goetze JP; Iversen JS; Jensen MT; Møgelvang R; Pedersen EB; Bech JN; Møller S
    Am J Physiol Gastrointest Liver Physiol; 2018 Feb; 314(2):G275-G286. PubMed ID: 29074483
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Plasma Nogo-A and placental growth factor levels are associated with portal hypertension in patients with liver cirrhosis.
    Gelman S; Salteniene V; Pranculis A; Skieceviciene J; Zykus R; Petrauskas D; Kupcinskas L; Canbay A; Link A; Kupcinskas J
    World J Gastroenterol; 2019 Jun; 25(23):2935-2946. PubMed ID: 31249451
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Circulating CXCL10 in cirrhotic portal hypertension might reflect systemic inflammation and predict ACLF and mortality.
    Lehmann JM; Claus K; Jansen C; Pohlmann A; Schierwagen R; Meyer C; Thomas D; Manekeller S; Claria J; Strassburg CP; Trautwein C; Wasmuth HE; Berres ML; Trebicka J
    Liver Int; 2018 May; 38(5):875-884. PubMed ID: 29105936
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Transjugular intrahepatic portosystemic shunt for portal vein thrombosis with symptomatic portal hypertension in liver cirrhosis.
    Han G; Qi X; He C; Yin Z; Wang J; Xia J; Yang Z; Bai M; Meng X; Niu J; Wu K; Fan D
    J Hepatol; 2011 Jan; 54(1):78-88. PubMed ID: 20932597
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Right atrial pressure is not adequate to calculate portal pressure gradient in cirrhosis: a clinical-hemodynamic correlation study.
    La Mura V; Abraldes JG; Berzigotti A; Erice E; Flores-Arroyo A; García-Pagán JC; Bosch J
    Hepatology; 2010 Jun; 51(6):2108-16. PubMed ID: 20512998
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 8.